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iruses are intracellular pathogens that are subject to 
intense selective pressures during their ongoing battles 
within the host. To propagate successfully, they must 
exploit numerous machineries of the infected cell. Thus, 
studies of their replicative cycles have yielded fundamental 
insights into eukaryotic biology. A prime example is the 
human immunodeﬁ  ciency virus (HIV), which is a lentivirus 
that causes the acquired immunodeﬁ  ciency syndrome 
(AIDS). Unlike simpler oncoviruses that rely exclusively on 
host cell machinery, lentiviruses code for additional accessory 
and regulatory proteins that act as molecular switches at 
different stages of viral entry and exit from the infected 
cell. Studying the actions of these viral proteins has yielded 
understanding of diverse cellular functions such as the innate 
immunity against retroviruses, control of transcriptional 
elongation, export of macromolecules from the nucleus 
to the cytoplasm, and intracellular trafﬁ  cking of proteins 
(reviewed in [1]). 
The transcriptional transactivator (Tat) is a key regulatory 
protein of HIV. It is expressed early after the virus 
integrates into the cell, and stimulates the elongation of 
RNA polymerase II (RNAPII). This type of transcriptional 
control had not been previously appreciated; thus, work on 
Tat established a new paradigm in the ﬁ  eld of eukaryotic 
biology. Moreover, these ﬁ  ndings impacted greatly studies 
of cotranscriptional processing of nascent mRNA. To 
understand these processes better, we need to start with the 
basics of transcriptional control.
RNAPII is the enzyme that transcribes protein-coding genes 
in eukaryotic cells. Elegant studies in vitro ﬁ  rst suggested that 
the simple recruitment of RNAPII to transcription units was 
not sufﬁ  cient for the copying of genes and cotranscriptional 
processing of their transcripts. Rather, distinct steps could be 
deﬁ  ned, which began with the assembly of the preinitiation 
complex (PIC), promoter clearance, pausing, and arrest, and 
ended with efﬁ  cient elongation of transcription (reviewed 
in [2]). The central component of PIC is the general 
transcription factor (GTF) TFIID, which contains the TATA-
box-binding protein (TBP) and 12 to 15 TBP-associated 
factors (TAFs). TFIID acts as a “landing pad” for other GTFs 
and RNAPII to nucleate PIC assembly. Moreover, TAFs serve 
as coactivators to a diverse set of activators. Both an ordered 
stepwise assembly and the recruitment of the 100-plus-subunit 
“holoenzyme” have been proposed to be critical for the 
positioning of RNAPII at start sites of transcription. 
Next, the GTF TFIIH unwinds the DNA, opens the 
transcription bubble, and phosphorylates serines at 
position 5 in the C-terminal domain (CTD) of the RPB1 
subunit of RNAPII (reviewed in [2]). This phosphorylation 
is critical for the recruitment of complexes that put a 
7-methylguanylate cap on the 5′ end of nascent transcripts. 
After the transcription complex clears the promoter, the 
negative transcription elongation factor (N-TEF) is recruited 
to the RNAPIIa (reviewed in [3]). It consists minimally of 5,6-
dichloro-1-β-D-ribofuranosylbenzimidazole riboside (DRB)-
sensitivity-inducing factor (DSIF) [4] and negative elongation 
factor (NELF) [5]. They bind and arrest RNAPII distal to 
the promoter cooperatively. Such arrested transcription 
complexes have now been found on many inducible genes in 
Drosophila melanogaster (reviewed in [6]) and humans [7]. 
The transition to robust elongation depends on the positive 
transcription elongation factor b (P-TEFb) (reviewed in [3]). 
P-TEFb contains the cyclin-dependent kinase 9 (CDK9) and 
one of four possible C-type cyclins. When recruited to stalled 
transcription complexes, P-TEFb phosphorylates serines at 
position 2 in the CTD [8], the Spt5 subunit of DSIF [9], and 
the RD subunit of NELF [10]. These modiﬁ  cations result in 
heavily phosphorylated RNAPII (RNAPIIo), the recruitment 
of the Elongator, which contains splicing and polyadenylation 
machineries, and the conversions of DSIF and NELF into 
elongation factors. RNAPIIo now copies the gene and 
directs the cotranscriptional processing, i.e., splicing and 
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polyadenylation, of primary transcripts. Upon successful 
polyA addition, the CTD phosphatase FCP1 dephosphorylates 
RNAPIIo. RNAPIIa dissociates from DNA, and the 
transcription cycle starts all over again (reviewed in [2]).
Tat is unique among transcriptional activators in 
eukaryotic cells in that it functions via RNA rather than DNA 
promoter elements (Figure 1). It binds the transactivation 
response element (TAR) that forms a stable RNA stem 
loop at the 5′ end of all viral transcripts. Thus, Tat requires 
minimally the transcription of TAR before it can stimulate 
HIV transcription from the long terminal repeat (LTR). 
Indeed, in the absence of Tat, RNAPIIa clears the HIV 
LTR successfully but soon arrests, yielding predominantly 
short viral transcripts [11]. Tat binds the 5′ bulge in TAR 
via its arginine-rich motif from positions 49 to 57, where a 
central arginine (R52) is key for this interaction. However, 
this binding is not sufﬁ  cient for Tat’s function in vivo. 
Adjacent to the arginine-rich motif lie N-terminal core and 
cysteine-rich regions, which form the activation domain of 
the protein. This activation domain binds cyclin T1 (CycT1) 
from P-TEFb, whose partner is CDK9 [12]. As a consequence, 
P-TEFb and Tat bind TAR cooperatively. The ﬁ  nal proof that 
P-TEFb is the cellular cofactor for Tat came from studies of 
HIV transcription in murine cells, where the introduction 
of the human CycT1 protein restores Tat function [12]. The 
same effect can be achieved by substituting just the tyrosine 
with the cysteine at position 261, such as are found in murine 
and human CycT1 proteins, respectively [13]. A paper in 
this issue of PLoS Biology suggests that Tat and P-TEFb can 
also recruit TAF-independent transcription complexes to 
the HIV LTR [14] (Figure 1). Possibly, this assembly reﬂ  ects 
interactions between CycT1 and the unphosphorylated CTD 
of RNAPIIa [15].
The assembly and disassembly of the complex between P-
TEFb, Tat, and TAR is a regulated process in vivo. Whereas 
the phosphorylation of CDK9 strengthens this complex [16], 
the acetylation of the lysine at position 50 in Tat weakens 
it [17]. Upon this disruption, acetylated Tat is liberated 
from P-TEFb and recruits the p300/CREB-binding protein–
associated factor (P-CAF) to the elongating RNAPIIo, most 
likely facilitating chromatin remodeling. In this issue of PLoS 
Biology, Pagans et al. now demonstrate that acetylated Tat is 
deacetylated by SIRT1 [18] (Figure 1). In this way, Tat can 
reassemble with P-TEFb on TAR.
Clearly, P-TEFb plays a key role in the control of 
transcriptional elongation. Although Tat was the ﬁ  rst 
activator known that could recruit P-TEFb to initiating 
RNAPII, additional members of this group were soon 
identiﬁ  ed. They include the androgen receptor, c-Myc, 
the class II transactivator (CIITA), myoblast determination 
protein (MyoD), and nuclear factor κ-B (NF-κB). The last 
one is of great interest as it explains how the HIV genome 
can be transcribed before the synthesis of Tat [19]. Cellular 
activation triggers the nuclear translocation of NF-κB, where 
it binds the HIV enhancer, leading to the stimulation of viral 
transcription. It is not surprising that proviral latency, in 
which low levels of transcription or only short HIV transcripts 
containing TAR are observed, would in large part reﬂ  ect the 
absence of these activators. Indeed, in many of these latently 
infected cells, the induction of NF-κB or the addition of Tat 
leads to the reactivation of viral replication and spreading of 
the infection [20,21]. 
Recently, important aspects of the regulation of P-TEFb 
have been revealed (Figure 2). Of interest, P-TEFb exists 
in two complexes in cells [22,23]. The larger measures 
approximately 500 kDa and contains the hexamethylene 
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Figure 1. Activation of HIV Transcription by Tat
Activators (red circles) that bind the HIV LTR promoter (light-blue rectangle) assemble the PIC and recruit RNAPIIa to the start site 
of transcription. For simplicity, only RNAPIIa in the PIC is presented. The yellow sphere with two open circles, depicting serines at 
position 5 and 2 within the CTD (S5 and S2, respectively), represents the unphosphorylated CTD of RNAPIIa (white sphere). TFIIH, 
which performs DNA-helicase and CTD-kinase activities, melts the DNA and phosphorylates S5 (red circle in the CTD; P-S5), resulting 
in promoter clearance. RNAPIIa transcribes TAR (red hairpin) and is paused by the binding of N-TEF, DSIF, and NELF, which are 
presented as blue spheres. The RD subunit of NELF binds the bottom stem in TAR. P-TEFb (comprising the red [CDK9] and pink 
[CycT1] spheres), which binds TAR together with Tat (small red sphere), phosphorylates S2 (red circle in the CTD; P-S2) to form 
elongating RNAPIIo (large red sphere). It also phosphorylates Spt5 in DSIF and RD in NELF, which become elongation factors, with 
the latter dissociating from TAR. In addition, P-TEFb, possibly independent of its kinase activity, assembles PIC via recruitment of TBP 
and RNAPIIa (dotted arrow). The phosphorylated CTD in RNAPIIo now binds the Elongator, which contains splicing machinery and 
polyadenylation factors. The red sphere at the 5′ end of the HIV transcript (red line) represents its cap. Finally, p300 acetylates Tat 
(magenta circle) and dissociates it from TAR. Acetylated Tat binds P-CAF and transfers it to RNAPIIo, possibly facilitating chromatin 
remodeling. Collectively, efﬁ  cient RNAPII elongation of viral transcription ensues.PLoS Biology  |  www.plosbiology.org 0202
bisacetamide (HMBA)–induced protein 1 (HEXIM1) and 
7SK small nuclear RNA (snRNA) in addition to P-TEFb 
[24,25]. In this large complex, Cdk9 is enzymatically inactive. 
HEXIM1 was identiﬁ  ed as the inducible gene following 
the exposure of vascular smooth muscle cells to a potent 
differentiating agent, HMBA [26]. 7SK snRNA is one of the 
most abundant snRNA species, whose function remained a 
mystery for over a decade. Of interest, targeting of P-TEFb 
by HEXIM1 and 7SK snRNA contributes signiﬁ  cantly to 
the control of cell growth and differentiation. For example, 
growth signals liberate P-TEFb from the large complex in the 
course of cardiac hypertrophy in mice, a disease characterized 
by the enlargement of myocytes due to a global increase in 
mRNA synthesis [27]. Also, following stress, ultraviolet light, 
or the administration of actinomycin D and DRB to cells, the 
large complex is converted to the small complex to stimulate 
transcription [22,23]. 
How central is P-TEFb to eukaryotic transcription? In 
Saccharomyces cerevisiae, there are two candidates for P-
TEFb, CTDK-1 and Bur1/2. CTDK1-negative but not 
Bur1/Bur2-negative yeasts still grow, albeit poorly and 
only on rich media (reviewed in [2]). In Caenorhabditis 
elegans, genetic inactivation of CDK9 or CycT1 and CycT2 
resulted in the inhibition of all RNAPII transcription 
[8]. Moreover, in D. melanogaster, following heat shock, P-
TEFb is recruited upstream of activated promoters [28]. 
Although no murine knockouts of subunits of P-TEFb have 
been reported, DRB and ﬂ  avopiridol, two ATP analogs 
that inhibit the kinase activity of CDK9, can inhibit nearly 
all transcription by RNAPII in human cells [29]. Indeed, 
as P-TEFb is a coactivator of potent activators that mediate 
effects of enhancers and can itself activate transcription 
when placed on sites distal to promoter elements [15], 
it might mediate many more signaling events than those 
of heat shock, ultraviolet light, stress, and hypertrophy. 
Conversely, the inhibition of P-TEFb could explain the 
mode of action of some transcriptional repressors. Indeed, 
the global transcriptional repressor PIE-1, the regulator of 
embryogenesis in C. elegans, binds the histidine-rich stretch 
in CycT1, thus decoying P-TEFb away from RNAPII and 
blocking the elongation of transcription [30]. 
These are exciting ﬁ  ndings and suggest a plethora of future 
experiments, including the genetic inactivation of subunits 
of P-TEFb and isoforms of HEXIM1 in the mouse. Of special 
interest are questions as to where to place this mechanism of 
transcriptional regulation in the hierarchy of competing or 
complementary processes. What roles do different P-TEFb 
complexes play in the transcription of speciﬁ  c genes? How 
central will the regulation of P-TEFb be to cellular growth, 
proliferation, and differentiation, and what roles will it play 
in normal development and disease states? As to HIV, how 
can we use our knowledge of P-TEFb to slow down viral 
replication and/or to eliminate the state of proviral latency 
in the host? Obviously, we are only at the beginning of this 
journey, which promises to change radically our view of 
eukaryotic transcription.  
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